General information

Announcements(0)

Program

Sessions

Search presentations

Timetable

Wed. Dec 3, 2025

Thu. Dec 4, 2025

Fri. Dec 5, 2025

web_header_en.png

web_icon.png

Profile management

Announcements

Bookmark

Download PDF for print

Program Type

Login required to view

Password required to view

Presentation Information

Session Details

Please enter the password printed on your name card.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

FEN1 counteracts 53BP1-dependent replication stress induced by a thymidine analog, alovudine (ALV)

Many genetic disorders have extremely poor prognoses, with only a limited window of opportunity between diagnosis and the initiation of treatment. In recent years, advances in genomic diagnostic technologies, along with emerging therapeutic approaches such as gene therapy and nucleic acid-based medicine, have been anticipated as groundbreaking treatment strategies for rare and intractable diseases. Furthermore, new discoveries in basic medicine and biology are accelerating these developments. This symposium will present the latest research findings contributing to the diagnosis and treatment of refractory genetic diseases from multiple perspectives.

【J】Genome Medicine and Genome Metabolism, Response, and Repair

The 48th Annual Meeting of the Molecular Biology Society of Japan

Presentation Information

[2MS-01-01]FEN1 counteracts 53BP1-dependent replication stress induced by a thymidine analog, alovudine (ALV)

Comment